Axiogenesis iPSC - iPSC (ID:70001)
HMS LINCS ID: | 70001 |
Name: | Axiogenesis iPSC |
Alternative Names: | iPSCs derived from human dermal fibroblasts by Ncardia, previously Axiogenesis |
LINCS ID: | |
Alternative ID: | |
Parent Primary Cell: | |
Citation Information for Mutations: | |
Molecular Features: | |
Passaging Method: | |
Passage Last Karyotyping: | |
Recommended Culture Conditions: |
Complete culture medium recipe: 450mL IMDM (PAN,P04-20150) 500μL Insulin (Insulin solution human, I9278, Sigma) 50mL Fetal calf serum (heat inactivated) Thioglycerol (400 μM)BMCC serum free culture medium recipe: 500ml IMDM (PAN,P04-20150) 500μl Insulin (Insulin solution human, I9278, Sigma) 5ml CD-Lipids (CD Lipids concentrate, 11905-031, Gibco) 500μl Trace Elements A ( 25-021-CI, Cellgro) 500μl Trace Elements B ( 99-175-CI, Cellgro) 500μl Trace Elements C (99-176-CI, Cellgro) 250μl Vitamin C ( 100mg/ml Stock) Thioglycerol (400 μM) |
Molecular Features: | |
Related Projects: | |
Cell Markers: | |
Genetic Modification(s): | |
Production Details: | generated using the Yamanaka protocol (inducing factors Oct3/4, Sox2, Klf4, c-Myc) |
Comments: | |
Date Publicly Available: | 2017-09-29 |
Most Recent Update: | 2018-03-20 |
Batch Information for HMSL70001-1:
HMS LINCS Batch ID: | 70001-1 |
Provider: | Ncardia, previously Axiogenesis |
Provider Catalog ID: | |
Provider Batch ID: | |
Source Information: | |
Date Received: | |
HMS QC Outcome: | |
Culture Conditions: | |
Passage Number: | |
Transient Modification(s): | |
Comments: | |
Date Publicly Available: | 2017-09-29 |
Most Recent Update: | 2018-03-20 |